/PRNewswire/ Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of.
CLSN Stock: Why Biotech Celsion Is Soaring Today CLSN is on the rise after getting fast-track approval from the FDA Feb 22, 2021, 10:29 am EDT February 22, 2021
Celsion (NASDAQ:
CLSN) stock was on the rise Monday after announcing fast-track approval from the U.S. Food and Drug Administration (FDA). This covers the treatment of advanced ovarian cancer from the company.
Source: Shutterstock
The fast-track status is for GEN-1. This is a DNA-mediated interleukin-12 (IL-12) immunotherapy designed to treat ovarian cancer. The company notes that this treatment is currently being tested in a Phase II clinical trial.
The fast-track designation comes after Celsion shared data from the Phase 1 study of combining GEN-1 with neoadjuvant chemotherapy with the FDA. That includes seven out of eight patients in the study seeing complete tumor resection. For comparison, just neoadjuvant chemotherapy alone had a 50% resection rate.
Press release content from Accesswire. The AP news staff was not involved in its creation.
Najib Babul Discusses Erythropoietic Protoporphyria for a Severe Photodermatosis
January 8, 2021 GMT
CLARK COUNTY, NV / ACCESSWIRE / January 7, 2021 / Erythropoietic protoporphyria (EPP) is a devastating lifelong disorder characterized by dermal photosensitivity with only one recently approved treatment and very few evidence-based clinical management tools. Dr. Najib Babul, an experienced drug development and regulatory affairs consultant discusses this serious debilitating condition.
EPP is a rare inherited disorder of heme biosynthesis characterized by dermal photosensitivity secondary to a partial deficiency of ferrochelatase. In a phenotypically similar X-linked protoporphyria (XLP), there is overactivity of the heme biosynthesis enzyme, erythropoietic aminolevulinate synthase (ALAS2). Both EPP and XLP result in the accumulation of the photosensitizer protoporphyrin IX (PPIX) in erythro
Cinergen: Najib Babul Discusses Erythropoietic Protoporphyria for a Severe Photodermatosis
CLARK COUNTY, NV / ACCESSWIRE / January 7, 2021 / Erythropoietic protoporphyria (EPP) is a devastating lifelong disorder characterized by dermal photosensitivity with only one recently approved treatment and very few evidence-based clinical management tools. Dr. Najib Babul, an experienced drug development and regulatory affairs consultant discusses this serious debilitating condition.
EPP is a rare inherited disorder of heme biosynthesis characterized by dermal photosensitivity secondary to a partial deficiency of ferrochelatase. In a phenotypically similar X-linked protoporphyria (XLP), there is overactivity of the heme biosynthesis enzyme, erythropoietic aminolevulinate synthase (ALAS2). Both EPP and XLP result in the accumulation of the photosensitizer protoporphyrin IX (PPIX) in erythrocytes, plasma, skin and liver. The accumulated PPIX is activated by sun exposure, thus generating free